Skip to main content
Download PDF

Association between PPARγ, PPARGC1A, and PPARGC1B genetic variants and susceptibility of gastric cancer in an Eastern Chinese population

BMC Medical Genomics volume 15, Article number: 274 (2022) Cite this article

Abstract

Purpose

Previous studies showed that peroxisome proliferator-activated receptor gamma (PPARγ) and PPARγ coactivator1 family (PPARGC1A and PPARGC1B) gene single nucleotide variants (SNVs)were strongly associated with cancer susceptibility. The purpose of this study was to investigate the association of PPARγ, PPARGC1A, and PPARGC1B variants with the risk of gastric cancer (GC).

Patients and methods

We performed a case-control study of 490 GC cases and 1,476 healthy controls from eastern China. PPARγ rs1801282 C > G, rs3856806 C > T, PPARGC1A rs2970847 C > T, rs8192678 C > T and PPARGC1B rs7732671 G > C, rs17572019 G > A SNVs were selected to investigate the association between these SNVs and GC susceptibility. Genotypes of the SNVs were assessed by multiplex fluorescent PCR using a custom-by-design 48-Plex SNPscantm Kit.

Results

The PPARγ rs1801282 SNV was associated with a decreased risk for GC (GC vs. CC: odds ratio (OR) = 0.62, 95% confidence interval (95%CI) = 0.42–0.93, adjusted P = 0.019; GC + GG vs. GG: OR = 0.63 95%CI = 0.42–0.93, adjusted P = 0.019; respectively). In addition, stratified analysis revealed that the PPARγ rs1801282 SNV was correlated with the risk of GC in subgroups of age ≥ 61, no smoking, and no alcohol consuming. We also confirmed that the PPARγ rs3856806 C > T SNV promoted the risk of GC in women. The PPARGC1A rs8192678 TT genotype decreased the susceptibility of GC in men. The PPARGC1A rs2970847 C > T SNV decreased the susceptibility of GC in the subgroup of BMI ≥ 24 kg/m2. The PPARGC1B rs7732671 G > C and rs17572019 G > A SNVs promoted the risk of GC in the subgroup of BMI ≥ 24 kg/m2.

Conclusion

This study indicates that the PPARγ, PPARGC1A, and PPARGC1B SNVs may be associated with the susceptibility of GC in eastern Chinese population. Future studies with larger populations, detailed H. pylori infection status for subgroup analysis, and functional study are needed to further clarify the relationship between these SNVs and GC risk.

Peer Review reports

Introduction

Gastric cancer (GC) accounts for more than 5% of all new cancer cases worldwide, making it the fifth most common cancer and the third leading cause of cancer-related deaths [1]. China is the worst affected, accounting for 45% of all cancer-related deaths and 42.6% of the incidence [2]. Notably, GC is often diagnosed at an advanced stage due to the lack of effective diagnostic markers, leading to a poor prognosis with a 5-year survival rate of below 40% [3]. Various risk factors influence the incidence of GC, such as microbial infections, genetic factors, alcohol, dietary regime, and obesity [4]. Many hereditary factors were found to play an impact on susceptibility to GC.

Peroxisome activated receptor gamma (PPARγ), a type II nuclear receptor gene, located on chromosome 3p25, is a member of the peroxisome activated receptor (PPAR) superfamily involved in adipogenesis, lipid metabolism, cell proliferation, chronic inflammation, and insulin sensitivity [5]. The aberrant PPARγ signaling pathway was associated with the development of obesity, diabetes, and cancers [6]. PPAR is overexpressed in various malignant tissues, including breast, esophageal, gastrointestinal, and prostate cancers [7]. Several studies suggested that PPARγ expression was associated with the prognosis of various tumors, including cancers of the breast, pancreas, and colorectum [8,9,10]. When activated by ligands, PPAR can act as a tumor suppressor by inducing tumor cell differentiation, inhibiting proliferation, promoting apoptosis, and reducing tumorigenic angiogenesis [11, 12]. PPAR receptor agonists exert inhibitory effects on various types of tumor cells and exert synergistic effects on chemotherapy and radiotherapy [13,14,15]. PPARGC1A and PPARGC1B are transcriptional coactivators of the PPAR superfamily, which share a high sequence identity [16,17,18]. They are well-established as master regulators of oxidative phosphorylation and fatty acid oxidation gene expression and are highly expressed in oxidative tissues such as brown adipose tissue, heart, kidney, skeletal muscle, and brain [19, 20]. The PPARGC1 family has been reported to play an important role in cancer progression by promoting the expression of antioxidant genes, regulating the expression of vascular endothelial growth factor, and promoting glucose metabolism and adipogenesis [21,22,23]. Increased expression and activity of PPARGC1A in cancers of lung, prostate, cervical, breast, colon, and melanoma promoted cancer cell progression and chemoresistance [21, 24]. However, PPARGC1A expression was significantly lower in clear cell renal cell cancer tissues and associated with a favorable prognosis [25, 26]. PPARGC1B enhances the mitochondrial activity and anabolic profile, contributing to the development of hepatocellular and intestinal cancers [27, 28]. Estrogen-related receptor α (ERRα) was highly expressed in GC tissues and promoted cancer progression[29]. PPARGC1A, and PPARGC1B, are also co-activators of ERRα, which could be related to the development of GC.

Single nucleotide variant (SNV) is the most common type of genetic variant that affects gene expression through different mechanisms and is associated with genetic susceptibility to cancer [30]. In the previous studies, we compared the PPARγ, PPARGC1A, and PPARGC1B SNVs with susceptibility of esophageal, colorectal, and hepatocellular carcinomas [31,32,33]. Therefore, we assumed that PPARγ, PPARGC1A, and PPARGC1B SNVs might be effective susceptibility markers of GC. According to the previous studies [31,32,33,34,35], PPARγ rs1801282 C > G, rs3856806 C > T, PPARGC1A rs8192678 C > T rs2970847 C > T, and PPARGC1B rs7732671 G > C, rs17572019 G > A SNVs are chosen to investigate the association between these SNVs and GC risk in a Chinese cohort.

Materials and methods

This cohort is part of a previous study [35]. GC group were recruited from in patients of the Affiliated People’s Hospital of Jiangsu University (Zhenjiang, Jiangsu province, China) and the Affiliated Union Hospital of Fujian Medical University (Fuzhou, Fujian Province, China). Healthy controls were recruited from participants in health screening at the same hospitals. Only Han Chinese population of East China residents without autoimmune diseases or other malignancies were included. The main inclusion criteria for GC cases were sporadic newly diagnosed primary GC patients with pathological confirmation; while GC cases who underwent chemotherapy prior to blood sample collection were excluded from the cohort. Healthy controls were age and gender-matched volunteers who underwent health checkups and were excluded from autoimmune diseases or malignancies. Demographic information and correlated risk factor were obtained through medical records and supplemental interviews. All participants enrolled were voluntary and signed an informed consent document in advance. The protocol was approved by the institutional ethics committees of Fujian Medical University (No.K201433).

DNA extraction and genotyping

In this study, 2mlEDTA anticoagulant fasting peripheral venous blood was donated by each participant and stored at -70℃ until DNA extraction was performed. Genomic DNA extraction was conducted by using a commercial blood DNA extraction kit (Promega, Madison, USA) following the procedure according to the manufacturer’s instructions.

Simply put, cryopreserved blood samples were water bath thawing. After erythrocyte lysis and removal, nuclear release, protein precipitation, and removal, genomic DNA precipitation, and re-dissolve, genomic DNA was obtained. The concentration and purity of DNA were assayed for quality control by a microspectrophotometer.

As with the prior, the genotypes of the six SNVs were assessed by multiplex fluorescent PCR using a custom-by-design 48-Plex SNPscantm Kit (Genesky Biotechnologies Inc., Shanghai, China) [34]. For quality control, seventy-nine samples (4%) were randomly drawn and retested. No alteration in the result of the genotype was found.

The genotype frequency of each SNV in the control group was tested for deviation from Hardy-Weinberg equilibrium (HWE) by Pearson’s goodness-of-fit chi-square using online Chi-square software (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). Genotype frequencies of the SNVs variants were compared using a Chi-square test (χ2) or Fisher’s exact test among GC cases and controls. The relationship of the SNVs with susceptibility to GC was assessed by Multivariate logistic regression analysis to estimate by odds ratios (ORs) and 95% confidence intervals (CIs). The student’s t-test and chi-square (χ2) test were used to compare continuous variables and discrete variables between CG patients and healthy controls, respectively. A P < 0.05 (two-tailed) was considered statistically significant. All statistical analyses performed in the present study were conducted using the SPSS software package (SPSS, Inc., version 19.0, Chicago, Illinois, USA).

Result

Clinical characteristics

The Demographic variables and risk factors of the cohort are summarized in Table 1. A total of 1,966 subjects (490 GC cases and 1,476 health controls) were recruited for our study. No significant differences were found between GC patients and healthy controls in terms of gender and age ( Age: P = 0.026, Sex: P = 0.891). Thus, GC cases and controls were well matched. However, there was a significant higher in tobacco smoking, alcohol consumption, and body mass index (BMI) < 24 (kg/m2) in GC cases than in healthy controls (Alcohol use: P < 0.001, Smoking status: P = 0.001, BMI: P < 0.001 ).

Table 1 Distribution of selected demographic variables and risk factors in GC patients and controls
Full size table

Data quality

As summarized in Table 2, the MAF values (minor allele frequency) of our controls were similar to the values for Chinese in the database.

Table 2 Primary information for PPARγ rs1801282 C > G, rs3856806 C > T, PPARGC1A rs8192678 C > T, rs2970847 C > T, PPARGC1B rs7732671 G > C, rs17572019 G > A polymorphisms
Full size table

Five P values of the SNVs rs1801282, rs3856806, rs8192678, rs2970847, rs7732671, and rs17572019) from Hardy–Weinberg equilibrium (HWE) test were more than 0.05 (P = 0.881, 0.954, 0.492, 0.497, 0.139 respectively). However, the genotype distribution of rs3856806 variants did not reach HWE (P = 0.026).

Overall, all genotyping successful rates for the SNVs were > 95%, suggesting that the study met the requirements of molecular epidemiology.

Association of PPARγ, PPARGC1A, and PPARGC1B SNVs with risk of GC

The distribution of genotypes and genotype frequencies are summarized in Table 3. We found that both in the additive and dominant model, the PPARγ rs1801282 SNV was associated with a decreased risk for GC (additive model: GC vs. CC: P = 0.033; dominant model: GC + GG vs. GG: P = 0.032; respectively). After adjusting for age, gender, BMI, smoking status, and alcohol consumption, the results remained statistically significant (GC vs. CC: adjusted P = 0.019; GC + GG vs. GG: adjusted P = 0.019; respectively). However, no significant relationship was found between GC risk and other genotypes assayed in genetic models (PPARγ rs3856806 C > T; PPARGC1A rs2970847 C > T; PPARGC1A rs8192678 C > T; PPARGC1B rs17572019 and PPARGC1Brs7732671).

Table 3 Logistic regression analyses of associations between PPARγ rs1801282 C > G, rs3856806 C > T, PPARGC1A rs8192678 C > T, rs2970847 C > T, PPARGC1B rs7732671 G > C, rs17572019 G > A polymorphisms and risk of GC
Full size table

Stratified analyses of the association of PPARγ, PPARGC1A, and PPARGC1B SNVs with the risk of GC

To determine whether the effects of these SNVs were modified by factors such as smoking, age, sex, alcohol consumption, and BMI, a stratified analysis was performed(Table 4, Table S1-5). For PPARγ rs1801282 C > G SNV, stratified analysis revealed that this variant constituted a GC protective factor in subgroups of age ≥ 61 years, no smoking, and no alcohol consuming (age ≥ 61years: additive model: GC vs. CC: adjusted P = 0.043; no smoking: additive model: GC vs. CC: adjusted P = 0.033, dominant model: GC + GG vs. CC: adjusted P = 0.032; no alcohol consuming: additive model: GC vs. CC: adjusted P = 0.006, dominant model: GC + GG vs. CC: adjusted P = 0.008; respectively, Table 4).

Table 4 Stratified analyses between PPARγ rs1801282 C > G polymorphism and GC risk by sex, age, smoking status, alcohol consumption and BMI
Full size table

For PPARγ rs3856806 C > T SNV, stratified analysis revealed that this variant constituted a GC risk factor in females (additive model: CT vs. CC: adjusted P = 0.037; dominant model: CT + TT vs. CC: adjusted P = 0.038, Additional file 1: Supplementary Table S1).

For the PPARGC1A rs8192678 TT genotype, stratified analysis revealed that this variant constituted a GC protective factor in males. (homozygote model: TT vs. CC: adjusted P = 0.045, Additional file 2: Supplementary Table S2)

For PPARGC1Ars2970847 C > T SNV, stratified analysis revealed that this variant constituted a GC protective factor in subgroups of BMI ≥ 24 kg/m2. (additive model: CT vs. CC: adjusted P = 0.028, Additional file 3: Supplementary Table S3)

For PPARGC1B rs7732671 G > C SNV, stratified analysis revealed that this variant constituted a GC risk factor in subgroups of BMI ≥ 24 kg/m2. (additive model: GC vs. GG: adjusted P = 0.027; dominant model: GC + CC vs. GG: adjusted P = 0.033, Additional file 4: Supplementary Table S4)

For PPARGC1B rs17572019 G > A SNV, stratified analysis revealed that this variant constituted a GC risk factor in subgroups of BMI ≥ 24 kg/m2. (additive model: GA vs. GG: adjusted P = 0.028; dominant model: GA + AA vs. GG: adjusted P = 0.034, Additional file 5: Supplementary Table S5)

Discussion

This study revealed that PPARγ rs1801282 C > G SNV was associated with a decreased risk for GC. In addition, PPARγ rs1801282 C > G SNV conferred decreased risk for GC patients among subgroups of age ≥ 61 years, no smoking and no alcohol consuming; PPARγ rs3856806 C > T SNV conferred risk for GC patients in females; PPARGC1A rs8192678 TT genotype conferred decreased risk for GC patients in male; PPARGC1A rs2970847 C > T conferred decreased risk for GC patients in a subgroup of BMI ≥ 24 kg/m2; both PPARGC1B rs7732671 G > C and PPARGC1B rs17572019 G > A conferred risk for GC patients in a subgroup of BMI ≥ 24 kg/m2.

The rs1801282 SNV has been reported to be associated with susceptibility to a variety of tumors. However, in some studies such as on breast and colorectal cancers, the correlation tended to vary by race and/or cancer type [34, 36,37,38,39,40,41,42]. Several studies focused on the association of rs1801282 SNV with the susceptibility of GC. An Iranian population-based study found that the rs1801282 SNV G allele increased the risk of non-cardia gastric cancer in people with H. pylori infection [43]. A Turkish-based study found that rs1801282 C > G SNV not only has an increased risk of GC but is also associated with poor differentiation and metastatic disease in GC [44]. Our study was based on eastern Chinese population, suggesting that rs1801282 SNV is a protective factor for GC, especially in the subgroup aged ≥ 61 years, non-smokers, and no alcohol consuming.

The impact of PPARγ on cancers is complex and bidirectional, PPARγ acts as a tumor promoter by induction of lipogenic gene ACLY, MIG12, FASN, and NR1F1, stem cell-related gene KLF4, ALDH and upregulation Nox1 ROS, and VEGF. PPARγ act as a tumor suppressor by inducing apoptosis through the upregulation of PTEN, suppression of NF-κB, and many other signaling pathways [7, 45, 46]. PPARγ mainly plays an anti-tumorigenesis role in GC. PPARγ expression was low in normal gastric mucosa and significantly higher in GC tissues and was an independent prognostic factor for GC [15, 47] . Enhanced PPARγ activity reduced GC cell migration, invasion, and EMT through upregulation of galectin-9 [47]. Increased expression of PPARγ may reduce proliferation and metastatic potential in GC by inhibiting TERT and ENAH through the Wnt/β-Catenin signaling pathway [48, 49].

Variants in the PPARγ affect gene transcription and expression, which has been intensively studied in metabolic diseases. An in vitro experiment demonstrated that rs1801282 SNV reduced the binding affinity of the receptor to the reactant and induced a reduction in transcriptional activity and was associated with lower BMI and improved insulin sensitivity [50, 51]. However, in a study on obesity, it was observed that the expression of PPARγ2 in subcutaneous fat was higher in heterozygote CG carriers than in the CC genotype [52]. Similar result was observed in another study on metabolic diseases, in which the PPARγ2 mRNA expression level in adipose tissue was higher in rs1801282 GG genotype carriers than in CC genotype carriers [53]. This supports our study to some exten that the rs1801282 heterozygous CG genotype may play an anti-tumorigenesis role in gastric cancer through overexpression of PPARγ2. However, studies on the function of rs1801282 SNV in GC are still lacking. A recent study examined PPARγ rs1801282 SNV in multiple human cancer cell lines, and a heterozygous CG genotype was detected in AGS and Caki-1 cancer cell lines. PPARγ mRNA expression in these cell lines was found to be lower than in cell lines with wild-type such as MCF10A, SK-BR-3, and MDA-MB-468 [54]. Therefore, the impact of rs1801282 SNV on the expression of the PPARγ may vary by tumor type and race. Further functional studies are needed to clarify the impact of rs1801282 SNV on GC.

Rs3856806 C > T variant, in exon 6, is a synonymous variant. It is an exon splice enhancement site that may reduce transcription of PPARγ [55]. There is a controversy between rs3856806 C > T variant and cancer susceptibility. In a study, the heterozygous CT genotype of rs3856806 was found to be protective against colorectal cancer, however, in contrast, studies by Jiang et al. and Lin et al. showed an increased risk of colorectal cancer with this genotype [31, 56, 57]. Similarly, several studies have been conducted on breast cancer susceptibility, but the results remain debated [38, 58, 59] . Recently, two meta-analyses reported that the PPARγ rs3856806 C > T variant increased overall cancer susceptibility [60, 61]. In a recent study of GC, rs3856806 SNV was found not related to cancer risk [62]. Our results suggested that PPARγ rs3856806 C > T constituted a risk factor for GC in women.

In GC tissues and GC cell lines, PPARGC1A expression was upregulated and associated with metastasis, invasion, and induce apoptosis of GC cells [63].  Rs8192678 SNV is the most well-studied variant of the PPARC1A, which substitutes glycine with serine at amino acid position 482 in exon 8. Research has also shown that the expression of PPARGC1A is significantly lower in those carrying the minor allele [64]. A study of prostate cancer showed no effect of rs8192678 SNV on cancer susceptibility [65]. In previous studies, the rs8192678 CT genotype represented a protective factor against colorectal cancer, and the rs8192678 TT genotype reduced esophageal squamous carcinoma risk [31, 33]. The present study showed that the rs8192678 TT genotype reduced GC susceptibility in men in a homozygote model. A study based on Spanish population showed that the rs8192678 C > T variant affects insulin sensitivity through a genotype-sex interaction. Men with T allele carriers have lower insulin sensitivity [66]. Since metabolic abnormalities are definite risk factors for gastric cancer, the rs8192678 SNV may affect the development of GC through a similar genotype-sex interaction. Relevant studies and evidence are still lacking and further research is needed.

PPARGC1A rs2970847 is a synonymous variant, which is reported associated with the risk of type 2 diabetes, obesity, and insulin resistance [67, 68]. In the previous studies, no association was found between PPARGC1A rs2970847 SNV and susceptibility of esophageal, colorectal, and hepatocellular carcinomas [31,32,33], however, the present study showed that it was a protective factor for GC in the group of BMI ≥ 24 kg/m2 in an Additive model. A study of an Iranian population revealed that rs2970847 SNV downregulates insulin signaling pathways and is associated with insulin resistance. Carriers of the T allele of rs2970847 had decreased performance of PPARGC1A and higher risk for obesity [69]. The correlation of rs2970847 with CG and other cancers is still lacking, and further studies are needed.

PPARGC1B is located on chromosome 5 and consists of 1023 amino acids. PPARGC1B is highly similar to PPARGC1A in terms of structure, function, and mechanism [70]. Studies showed that the PPARGC1B rs7732671 variant increases breast cancer risk and affects cancer progression [71, 72]. The risk of esophageal squamous carcinoma in the high alcohol intake subgroup was promoted by the PPARGC1B rs17572019 G > A SNV [33]. In the current study, both PPARGC1B rs7732671 G > C and rs17572019 G > A SNVs were found to be a risk factor for GC in the additive and dominant models in the group with BMI ≥ 24 kg/m2. A study on breast cancer found that rs7732671 G > C enhances ERRα and ERRγ signaling and modulates aerobic glycolysis [72].  Since the ERRα signaling pathway was shown to promote GC [29], further studies are needed to clarify whether rs7732671 SNV affects GC development through ERRα or other pathways.

To our knowledge, the present study is the largest sample size study to date exploring the relationship between PPARγ, PPARGC1A, PPARGC1B variants, and GC susceptibility. This study demonstrated that the PPARγ, PPARGC1A, and PPARGC1B SNVs were associated with genetic susceptibility to GC. It could be a potential biomarker in the prevention and screening of GC in the Chinese population. However, there were several limitations in this study. First, H. pylori infection status was inaccessible, which affect the further subgroup analysis. Second, since both the GC cases and controls were hospital-based, the potential selection bias might have occurred. Third, many other environmental and personal factors might be associated with the etiology of GC, such as socioeconomic status, literacy, and diet, but were not collected and analyzed adequately in this study.

In conclusion, this study indicates that the PPARγ rs1801282 C > G SNV was associated with a decreased risk for GC in eastern Chinese population. Future studies with larger populations, detailed H. pylori infection status, and functional studies are needed to further clarify the relationship between these SNVs and GC risk.

Availability of data and materials

The data that support the findings of the present are included in the supplementary information file named Additional file 7: Raw_data. The sequences of the primers are provided in the supplementary information file named Additional file 6: Supplementary_Primers.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  2. Wang W, Sun Z, Deng JY, Qi XL, Feng XY, Fang C, et al. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer. Cancer Commun (Lond). 2018;38(1):23.

    Article  Google Scholar 

  3. Berardi R, Scartozzi M, Romagnoli E, Antognoli S, Cascinu S. Gastric cancer treatment: a systematic review. Oncol Rep. 2004;11(4):911–6.

    Google Scholar 

  4. Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric Cancer: a systematic review. Asian Pac J Cancer Prev. 2018;19(3):591–603.

    CAS  Google Scholar 

  5. Gonzalez-Castro TB, Tovilla-Zarate CA, Juarez-Rojop IE, Hernandez-Diaz Y, Lopez-Narvaez ML, Rodriguez-Perez C, et al. PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease. Biomark Med. 2018;12(3):287–97.

    Article  CAS  Google Scholar 

  6. Zhu L, Huang Q, Xie Z, Kang M, Ding H, Chen B, et al. PPARGC1A rs3736265 G > A polymorphism is associated with decreased risk of type 2 diabetes mellitus and fasting plasma glucose level. Oncotarget. 2017;8(23):37308–20.

    Article  Google Scholar 

  7. Yun SH, Han SH, Park JI. Peroxisome proliferator-activated receptor gamma and PGC-1alpha in Cancer: dual actions as tumor promoter and suppressor. PPAR Res. 2018;2018:6727421.

    Article  Google Scholar 

  8. Forootan FS, Forootan SS, Gou X, Yang J, Liu B, Chen D, et al. Fatty acid activated PPARgamma promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter. Oncotarget. 2016;7(8):9322–39.

    Article  Google Scholar 

  9. Zhang Y, Luo HY, Liu GL, Wang DS, Wang ZQ, Zeng ZL, et al. Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor gamma overexpression in human pancreatic carcinoma. Int J Oncol. 2015;46(1):175–84.

    Article  CAS  Google Scholar 

  10. Yaghoubizadeh M, Pishkar L, Basati G. Aberrant expression of peroxisome proliferator-activated receptors in Colorectal Cancer and their association with Cancer Progression and Prognosis. Gastrointest Tumors. 2020;7(1–2):11–20.

    Article  CAS  Google Scholar 

  11. Ying S, Xiao X, Chen T, Lou J. PPAR ligands function as suppressors that target biological actions of HMGB1. PPAR Res. 2016;2016:2612743.

    Article  Google Scholar 

  12. Bojkova B, Kajo K, Garajova M, Kubatka P, Pec M, Kiskova T, et al. Rosiglitazone shows partial oncostatic effect in rat mammary carcinogenesis. Neoplasma. 2013;60(1):46–55.

    Article  CAS  Google Scholar 

  13. Skelhorne-Gross G, Nicol CJ. The Key to unlocking the chemotherapeutic potential of PPARgamma Ligands: having the right combination. PPAR Res. 2012;2012:946943.

    Article  Google Scholar 

  14. Youssef J, Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br J Pharmacol. 2011;164(1):68–82.

    Article  CAS  Google Scholar 

  15. Xu S, Xu X. Research advances in the correlation between peroxisome proliferator-activated receptor-gamma and Digestive Cancers. PPAR Res. 2018;2018:5289859.

    Article  Google Scholar 

  16. Kressler D, Schreiber SN, Knutti D, Kralli A. The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. J Biol Chem. 2002;277(16):13918–25.

    Article  CAS  Google Scholar 

  17. Bost F, Kaminski L. The metabolic modulator PGC-1alpha in cancer. Am J Cancer Res. 2019;9(2):198–211.

    CAS  Google Scholar 

  18. Lin J, Puigserver P, Donovan J, Tarr P, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. J Biol Chem. 2002;277(3):1645–8.

    Article  CAS  Google Scholar 

  19. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27(7):728–35.

    Article  CAS  Google Scholar 

  20. Gravel SP. Deciphering the Dichotomous Effects of PGC-1alpha on Tumorigenesis and Metastasis. Front Oncol. 2018;8:75.

    Article  Google Scholar 

  21. Cao J, Wang X, Wang D, Ma R, Li X, Feng H, et al. PGC-1beta cooperating with FOXA2 inhibits proliferation and migration of breast cancer cells. Cancer Cell Int. 2019;19:93.

    Article  Google Scholar 

  22. Deblois G, St-Pierre J, Giguere V. The PGC-1/ERR signaling axis in cancer. Oncogene. 2013;32(30):3483–90.

    Article  CAS  Google Scholar 

  23. Girnun GD. The diverse role of the PPARgamma coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol. 2012;23(4):381–8.

    Article  CAS  Google Scholar 

  24. Luo X, Liao C, Quan J, Cheng C, Zhao X, Bode AM, et al. Posttranslational regulation of PGC-1alpha and its implication in cancer metabolism. Int J Cancer. 2019;145(6):1475–83.

    Article  CAS  Google Scholar 

  25. Ma T, Meng L, Wang X, Tian Z, Wang J, Liu X, et al. TNFSF13B and PPARGC1A expression is associated with tumor-infiltrating immune cell abundance and prognosis in clear cell renal cell carcinoma. Am J Transl Res. 2021;13(10):11048–64.

    CAS  Google Scholar 

  26. Xu WH, Xu Y, Wang J, Wan FN, Wang HK, Cao DL, et al. Prognostic value and immune infiltration of novel signatures in clear cell renal cell carcinoma microenvironment. Aging. 2019;11(17):6999–7020.

    Article  CAS  Google Scholar 

  27. Piccinin E, Peres C, Bellafante E, Ducheix S, Pinto C, Villani G, et al. Hepatic peroxisome proliferator-activated receptor gamma coactivator 1beta drives mitochondrial and anabolic signatures that contribute to hepatocellular carcinoma progression in mice. Hepatology. 2018;67(3):884–98.

    Article  CAS  Google Scholar 

  28. D’Errico I, Salvatore L, Murzilli S, Lo Sasso G, Latorre D, Martelli N, et al. Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A. 2011;108(16):6603–8.

    Article  Google Scholar 

  29. Zhong Y, He K, Shi L, Chen L, Zhou B, Ma R, et al. Down-regulation of estrogen-related receptor alpha (ERRalpha) inhibits gastric cancer cell migration and invasion in vitro and in vivo. Aging. 2021;13(4):5845–57.

    Article  CAS  Google Scholar 

  30. Deng N, Zhou H, Fan H, Yuan Y. Single nucleotide polymorphisms and cancer susceptibility. Oncotarget. 2017;8(66):110635–49.

    Article  Google Scholar 

  31. Lin J, Chen Y, Tang WF, Liu C, Zhang S, Guo ZQ, et al. PPARG rs3856806 C > T polymorphism increased the risk of Colorectal Cancer: a case-control study in Eastern Chinese Han Population. Front Oncol. 2019;9:63.

    Article  Google Scholar 

  32. Zhang S, Jiang J, Chen Z, Wang Y, Tang W, Chen Y, et al. Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern chinese Han population. Onco Targets Ther. 2018;11:4651–60.

    Article  Google Scholar 

  33. Chen Z, Wang Y, Wang J, Kang M, Tang W, Chen S. Assessment of PPARGC1A, PPARGC1B, and PON1 genetic polymorphisms in esophageal squamous cell Carcinoma susceptibility in the Eastern Chinese Han Population: a Case-Control Study Involving 2351 subjects. DNA Cell Biol. 2020;39(9):1521–31.

    Article  CAS  Google Scholar 

  34. Jiang J, Xie Z, Guo J, Wang Y, Liu C, Zhang S, et al. Association of PPARG rs 1801282 C > G polymorphism with risk of colorectal cancer: from a case-control study to a meta-analysis. Oncotarget. 2017;8(59):100558–69.

    Article  Google Scholar 

  35. Liu J, Tang W, Lin W, Wang Y, Chen Y, Wang J, et al. Lack of Association between CTLA-4 genetic polymorphisms and noncardiac gastric Cancer in a Chinese Population. DNA Cell Biol. 2019;38(5):443–8.

    Article  CAS  Google Scholar 

  36. Vogel U, Christensen J, Nexo BA, Wallin H, Friis S, Tjonneland A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis. 2007;28(2):427–34.

    Article  CAS  Google Scholar 

  37. Wang Y, McCullough ML, Stevens VL, Rodriguez C, Jacobs EJ, Teras LR, et al. Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer. Anticancer Res. 2007;27(1B):589–93.

    CAS  Google Scholar 

  38. Wu MH, Chu CH, Chou YC, Chou WY, Yang T, Hsu GC, et al. Joint effect of peroxisome proliferator-activated receptor gamma genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case-control study in Taiwan. Breast Cancer Res Treat. 2011;127(3):777–84.

    Article  CAS  Google Scholar 

  39. Unal E, Aslan EI, Ozturk T, Kurnaz Gomleksiz O, Kucukhuseyin O, Tuzuner MB, et al. Peroxisome proliferator-activated receptor Gamma Pro12Ala/C161T genotypes and risky haplotype altering risk of breast Cancer: a turkish case-control study. Biochem Genet. 2021.

  40. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003;63(13):3560–6.

    CAS  Google Scholar 

  41. Koh WP, Yuan JM, Van Den Berg D, Ingles SA, Yu MC. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among chinese in Singapore. Carcinogenesis. 2006;27(9):1797–802.

    Article  CAS  Google Scholar 

  42. Crous-Bou M, Rennert G, Salazar R, Rodriguez-Moranta F, Rennert HS, Lejbkowicz F, et al. Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer. Mutagenesis. 2012;27(2):169–76.

    Article  CAS  Google Scholar 

  43. Bazargani A, Khoramrooz SS, Kamali-Sarvestani E, Taghavi SA, Saberifiroozi M. Association between peroxisome proliferator-activated receptor-gamma gene polymorphism (Pro12Ala) and Helicobacter pylori infection in gastric carcinogenesis. Scand J Gastroenterol. 2010;45(10):1162–7.

    Article  CAS  Google Scholar 

  44. Canbay E, Kurnaz O, Canbay B, Bugra D, Cakmakoglu B, Bulut T, et al. PPAR-gamma Pro12Ala polymorphism and gastric cancer risk in a turkish population. Asian Pac J Cancer Prev. 2012;13(11):5875–8.

    Article  Google Scholar 

  45. Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and development of PPAR modulators in Health and Disease: an update of clinical evidence. Int J Mol Sci. 2019;20(20).

  46. Park JI, Kwak JY. The role of peroxisome proliferator-activated receptors in colorectal cancer. PPAR Res. 2012;2012:876418.

    Article  Google Scholar 

  47. Cho SJ, Kook MC, Lee JH, Shin JY, Park J, Bae YK, et al. Peroxisome proliferator-activated receptor gamma upregulates galectin-9 and predicts prognosis in intestinal-type gastric cancer. Int J Cancer. 2015;136(4):810–20.

    Article  CAS  Google Scholar 

  48. Guo F, Ren X, Dong Y, Hu X, Xu D, Zhou H, et al. Constitutive expression of PPARgamma inhibits proliferation and migration of gastric cancer cells and down-regulates Wnt/beta-Catenin signaling pathway downstream target genes TERT and ENAH. Gene. 2016;584(1):31–7.

    Article  CAS  Google Scholar 

  49. From the American Association of Neurological Surgeons ASoNC, Interventional Radiology Society of Europe CIRACoNSESoMINTESoNESOSfCA, Interventions SoIRSoNS. World Stroke O, Sacks D, Baxter B, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612 – 32.

  50. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20(3):284–7.

    Article  CAS  Google Scholar 

  51. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000;268(1):178–82.

    Article  CAS  Google Scholar 

  52. Kolehmainen M, Uusitupa MI, Alhava E, Laakso M, Vidal H. Effect of the Pro12Ala polymorphism in the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on the expression of PPARgamma target genes in adipose tissue of massively obese subjects. J Clin Endocrinol Metab. 2003;88(4):1717–22.

    Article  CAS  Google Scholar 

  53. Pihlajamaki J, Schwab U, Kaminska D, Agren J, Kuusisto J, Kolehmainen M, et al. Dietary polyunsaturated fatty acids and the Pro12Ala polymorphisms of PPARG regulate serum lipids through divergent pathways: a randomized crossover clinical trial. Genes Nutr. 2015;10(6):43.

    Article  Google Scholar 

  54. Kurnaz H, Demircan G, Ebrahimi A, Kocak H. Investigation of peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and its effect on peroxisome proliferator-activated receptor-gamma mRNA expression in human cancer cell lines. Medicine Science | International Medical Journal. 2019;8(4).

  55. Krasznai M, Szaniszlo K, Kraxner H, Vargha E, Kovacs M, Kaszas E, et al. Association of PPAR polymorphisms with cytokine levels in allergic rhinitis. Eur Arch Otorhinolaryngol. 2012;269(2):513–21.

    Article  Google Scholar 

  56. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005;26(2):449–57.

    Article  CAS  Google Scholar 

  57. Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, et al. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an indian population. Cancer Sci. 2005;96(8):507–12.

    Article  CAS  Google Scholar 

  58. Unal E, Aslan EI, Ozturk T, Kurnaz Gomleksiz O, Kucukhuseyin O, Tuzuner MB, et al. Peroxisome proliferator-activated receptor Gamma Pro12Ala/C161T genotypes and risky haplotype altering risk of breast Cancer: a turkish case-control study. Biochem Genet. 2021;59(6):1413–26.

    Article  Google Scholar 

  59. Tang W, Chen Y, Wang Y, Gu H, Chen S, Kang M. Peroxisome proliferator-activated receptor gamma (PPARG) polymorphisms and breast cancer susceptibility: a meta-analysis. Int J Clin Exp Med. 2015;8(8):12226–38.

    CAS  Google Scholar 

  60. Xu W, Li Y, Wang X, Chen B, Liu S, Wang Y, et al. PPARgamma polymorphisms and cancer risk: a meta-analysis involving 32,138 subjects. Oncol Rep. 2010;24(2):579–85.

    Google Scholar 

  61. Ding H, Chen Y, Qiu H, Liu C, Wang Y, Kang M, et al. PPARG c.1347 C > T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis. Oncotarget. 2017;8(60):102277–90.

    Article  Google Scholar 

  62. Jeon C, Chang SC, Mu L, Zhao J, Rao JY, Lu QY, et al. Genetic variants of peroxisome proliferator-activated receptor delta are associated with gastric cancer. Dig Dis Sci. 2013;58(10):2881–6.

    Article  CAS  Google Scholar 

  63. Wang P, Guo X, Zong W, Li Y, Liu G, Lv Y, et al. PGC-1alpha/SNAI1 axis regulates tumor growth and metastasis by targeting miR-128b in gastric cancer. J Cell Physiol. 2019;234(10):17232–41.

    Article  CAS  Google Scholar 

  64. Zhang RN, Shen F, Pan Q, Cao HX, Chen GY, Fan JG. PPARGC1A rs8192678 G > A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27(25):3863–76.

    Article  CAS  Google Scholar 

  65. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, et al. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011;107(1):126–34.

    Article  CAS  Google Scholar 

  66. Montes-de-Oca-Garcia A, Corral-Perez J, Velazquez-Diaz D, Perez-Bey A, Rebollo-Ramos M, Marin-Galindo A, et al. Influence of peroxisome proliferator-activated receptor (PPAR)-gamma Coactivator (PGC)-1 alpha gene rs8192678 polymorphism by gender on different health-related parameters in healthy young adults. Front Physiol. 2022;13:885185.

    Article  Google Scholar 

  67. Yang Y, Mo X, Chen S, Lu X, Gu D. Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev. 2011;27(2):177–84.

    Article  Google Scholar 

  68. Song J, Liu YY, Long Y, Tian HM, Liu R, Li XJ, et al. [PPARGC1A gene Thr394Thr G/A polymorphism and its association with type 2 diabetes mellitus and insulin resistance in a chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010;27(5):550–3.

    CAS  Google Scholar 

  69. Moradi S, Mirzaei K, Maghbooli Z, Abdurahman AA, Keshavarz SA. Variants in the PPARGC1A gene may influence the Effect of Fat Intake on resting metabolic rate in obese women. Lipids. 2018;53(3):291–300.

    Article  CAS  Google Scholar 

  70. Bellafante E, Morgano A, Salvatore L, Murzilli S, Di Tullio G, D’Orazio A, et al. PGC-1beta promotes enterocyte lifespan and tumorigenesis in the intestine. Proc Natl Acad Sci U S A. 2014;111(42):E4523-31.

    Article  Google Scholar 

  71. Martinez-Nava GA, Burguete-Garcia AI, Lopez-Carrillo L, Hernandez-Ramirez RU, Madrid-Marina V, Cebrian ME. PPARgamma and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk. Biomarkers. 2013;18(6):493–501.

    Article  CAS  Google Scholar 

  72. Saladores PH, Hoppe R, Lo W-Y, Cocciardi S, Hofmann U, Hamann U, et al. Abstract 5485: Coactivator PPARGC1B Ala203Pro polymorphism is linked with estrogen-related receptor function and breast cancer outcome. Cancer Res. 2015;75(15_Supplement):5485-.

    Article  Google Scholar 

Download references

Acknowledgements

The authors appreciate all participants in this study. The authors thank Dr. Yan Liu (Genesky Biotechnologies, Inc., Shanghai, China) for technical support.

Funding

This study was supported by the Fujian Provincial Health and Family Planning Research Talent Training Program (2018-ZQN-13).

Author information

Author notes

  1. Boyang Chen, Yafeng Wang and Weifeng Tang contributed equally to this work

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, The Affiliated Hospital of Putian University, Putian, 351100, Fujian Province, China

    Boyang Chen, Mingqiang Kang & Jinbiao Xie

  2. Department of Cardiology, The People’s Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan Province, China

    Yafeng Wang

  3. Department of Cardiothoracic Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, China

    Weifeng Tang

  4. Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China

    Yu Chen

  5. Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

    Chao Liu

  6. Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian Province, China

    Mingqiang Kang

Authors
  1. Boyang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yafeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weifeng Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mingqiang Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jinbiao Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

B.C., Y.W., and W.T. carried out the whole experiments; W.T. and Y.W. statistically analyzed all the data and graphed; J.X., C.L., and Y.C. helped in assays; J.X., W.T., C.L., M.K., and Y.C. obtained the funds and organized the study. All authors read and approve the final version of the article and consent to its publication. 

Corresponding authors

Correspondence to Mingqiang Kang or Jinbiao Xie.

Ethics declarations

Ethics approval and consent to participate

The study protocol was conducted by the ethical standards of the Declaration of Helsinki II, and approved by the institutional ethics committees of Fujian Medical University (No.K201433). All participants enrolled were voluntarily and signed an informed consent document.

Consent for publication

Not applicable.

Competing interests

Authors have no conflict of interest, financial or otherwise.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1.

Supplementary Table S1.

Additional file 2.

Supplementary Table S2.

Additional file 3.

Supplementary Table S3.

Additional file 4.

Supplementary Table S4.

Additional file 5.

Supplementary Table S5.

Additional file 6.

Supplementary Primers.

Additional file 7.

Raw_data.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, B., Wang, Y., Tang, W. et al. Association between PPARγ, PPARGC1A, and PPARGC1B genetic variants and susceptibility of gastric cancer in an Eastern Chinese population. BMC Med Genomics 15, 274 (2022). https://doi.org/10.1186/s12920-022-01428-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12920-022-01428-0

Keywords

  • PPARγ
  • PPARGC1A
  • PPARGC1B
  • Variant
  • SNVs
  • Gastric cancer

BMC Medical Genomics

ISSN: 1755-8794

Contact us